What moves a hypoglycaemia rate most?

Background therapy. In SURPASS-4 the same compound showed 1–3% without a sulfonylurea and 6–9% overall.

Is the threshold standardised?

No. SURPASS-4 used glucose below 54 mg/dL or severe. Other thresholds count more or fewer events, making rates non-comparable.

Can effective glucose lowering itself raise the rate?

Yes. Moving closer to the lower end of the range makes ordinary fluctuation more likely to cross a threshold.

GLP-1 & Incretin Science

The Number Depends on Three Things Before the Drug

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A hypoglycaemia rate depends on what else participants were taking, what glucose threshold was used to define an event, and how far HbA1c fell. All three move the number substantially, sometimes more than the compound does.

Key facts

Factor 1: Background therapy
Factor 2: Threshold defining an event
Common threshold: Glucose below 54 mg/dL, or severe
Factor 3: Magnitude of HbA1c reduction
SURPASS-4 illustration: 1–3% vs 6–9%, same compound
Difference explained by: Sulfonylurea use

Background therapy moves it most

SURPASS-4 shows this directly. Hypoglycaemia occurred in 6 to 9% of tirzepatide participants overall, but in only 1 to 3% of those not taking a sulfonylurea. Same compound, same trial, same definition — and a several-fold difference produced entirely by what else was being taken.

The threshold is a choice, not a fact

SURPASS-4 counted events at glucose below 54 mg/dL or clinically severe. A trial using a higher threshold counts more events; one requiring assistance from another person counts far fewer. Rates from trials using different definitions are not comparable, and the definition is frequently omitted from summaries.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

How far glucose fell matters too

An agent lowering HbA1c further moves participants closer to the lower end of the range, where an ordinary fluctuation is more likely to cross a threshold. Some hypoglycaemia risk therefore tracks the effectiveness of glucose lowering rather than the mechanism producing it — which is the same pattern as retinopathy and rapid HbA1c reduction elsewhere on this site.

Why the comparator determines what the number means

Against placebo, an incretin will show more hypoglycaemia than nothing. Against insulin, considerably less — SURPASS-4 reported 19% with glargine against 6 to 9% with tirzepatide. Both comparisons are true and they support opposite-sounding statements, which is why the comparator belongs in any quoted figure.

The question to ask of any rate

On what background, by what definition, against what comparator, and at what degree of glucose lowering. A figure travelling without those four is not interpretable, and hypoglycaemia rates travel without them more often than most safety numbers.

What none of this is

Guidance. It describes how to read published trial data about licensed medicines given under clinical supervision. Nothing supplied on this site affects blood glucose, and decisions about diabetes treatment belong with a clinician.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What moves a hypoglycaemia rate most?: Background therapy. In SURPASS-4 the same compound showed 1–3% without a sulfonylurea and 6–9% overall.
Is the threshold standardised?: No. SURPASS-4 used glucose below 54 mg/dL or severe. Other thresholds count more or fewer events, making rates non-comparable.
Can effective glucose lowering itself raise the rate?: Yes. Moving closer to the lower end of the range makes ordinary fluctuation more likely to cross a threshold.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum